APA (7th ed.) Citation

AA, A., MA, R., RA, A., NF, A., FA, A., AS, A., . . . RFM, E. (2025). Correction: Awaji et al. Chemotherapeutic Activity of Imidazolium-Supported Pd(II) o-Vanillylidene Diaminocyclohexane Complexes Immobilized in Nanolipid as Inhibitors for HER2/neu and FGFR2/FGF2 Axis Overexpression in Breast Cancer Cells. Pharmaceuticals 2023, 16, 1711. Pharmaceuticals (Basel, Switzerland), 18(9), . https://doi.org/10.3390/ph18091287

Chicago Style (17th ed.) Citation

AA, Awaji, Rizk MA, Alsaiari RA, Alqahtani NF, Al-Qadri FA, Alkorbi AS, Hafez HS, and Elshaarawy RFM. "Correction: Awaji Et Al. Chemotherapeutic Activity of Imidazolium-Supported Pd(II) O-Vanillylidene Diaminocyclohexane Complexes Immobilized in Nanolipid as Inhibitors for HER2/neu and FGFR2/FGF2 Axis Overexpression in Breast Cancer Cells. Pharmaceuticals 2023, 16, 1711." Pharmaceuticals (Basel, Switzerland) 18, no. 9 (2025). https://doi.org/10.3390/ph18091287.

MLA (9th ed.) Citation

AA, Awaji, et al. "Correction: Awaji Et Al. Chemotherapeutic Activity of Imidazolium-Supported Pd(II) O-Vanillylidene Diaminocyclohexane Complexes Immobilized in Nanolipid as Inhibitors for HER2/neu and FGFR2/FGF2 Axis Overexpression in Breast Cancer Cells. Pharmaceuticals 2023, 16, 1711." Pharmaceuticals (Basel, Switzerland), vol. 18, no. 9, 2025, https://doi.org/10.3390/ph18091287.